Home | Welcome to Contract Pharma   
Last Updated Wednesday, April 23 2014
Print RSS Feed

Breaking News

Related Searches:
September 18, 2009
Wyeth and Ambrx, Inc. have formed a worldwide alliance to discover, develop, and commercialize protein drug candidates for three undisclosed targets.  Read More »
September 18, 2009
The FDA has approved Novartis’ Valturna (aliskiren and valsartan) tablets, a medicine targeting two key points within the renin system, also known as the renin angiotensin aldosterone system (RAAS), a regulator of blood pressure.  Read More »
September 18, 2009
Cambridge Regulatory Services (CambReg) has formed a strategic alliance with SIRO Clinpharm, a global Indian-based CRO, to provide services to pharma companies in both Asia and Europe.  Read More »
September 18, 2009
Penn Pharma has appointed Karl Fry as director of quality. Mr. Fry joins the company from a quality management role at sterile pharmaceutical manufacturer, Patheon in Swindon.  Read More »
September 17, 2009
ICON has received industry accreditations for three of its laboratories.  Read More »
September 17, 2009
GlaxoSmithKline and XenoPort, Inc. achieved positive results from a Phase IIb trial evaluating the safety and efficacy of GSK1838262/XP13512 (gabapentin enacarbil) for neuropathic pain associated with post-herpetic neuralgia (PHN) in adults.  Read More »
September 17, 2009
QPS Taiwan has been awarded a GLP lab certification by the Department of Health (DOH), Executive Yuan, R.O.C. (Taiwan).   Read More »
September 16, 2009
Bristol-Myers Squibb Co. has reached an agreement for the sale of its OTC assets in Asia Pacific (excluding China and Japan) to Taisho Pharmaceutical Co., Ltd. for $310 million.   Read More »
September 16, 2009
PPD, Inc. has opened its global central lab facility in Singapore to provide customized lab services in Southeast Asia.   Read More »
September 16, 2009
Lisa Rojkjaer, M.D. has been appointed vice president and head of clinical development at MorphoSys.  Read More »
September 15, 2009
In conjunction with Lilly’s recent restructuring initiative, the company has named the leaders of its Development Center of Excellence (CoE) and its five business units: oncology, diabetes, established markets, emerging markets, and Elanco animal he  Read More »
September 15, 2009
Alcon has entered into a definitive agreement to acquire ESBATech AG for $150 million in cash at closing, plus achievement-based R&D payments of as much as $439 million.  Read More »
September 15, 2009
Marc N. Casper has been appointed president, chief executive officer and a director of Thermo Fisher Scientific Inc., effective October 15, 2009.  Read More »
September 14, 2009
Revenues dropped in both manufacturing and development services  Read More »
September 14, 2009
Lilly has announced plans to restructure and shave $1 billion from its operating costs  Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On